Overview

A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The extension protocol is designed to allow those patients randomized to placebo in the core portion of the protocol to receive a 6 month treatment of open label octreotide and allow those patients randomized to octreotide who appeared to benefit from treatment, to continue to receive octreotide.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Octreotide